Effect of niravoline (RU51599), a kappa-opioid receptor agonist, on tumour-origin brain oedema.
Niravoline is a selective kappa-opioid receptor agonist. Its effect on tumour-origin brain oedema was investigated in a brain tumour model created by implantation of C6 glioma cells into the brain of Wistar rats. Five weeks after the tumour cell implantation, niravoline was administered i.v. at 1 mg/kg, a total of four times at one-hour intervals. In the control group (i.e., saline or vehicle-treated rats), this brain tumour model was found to result in a statistically significant increase in the water content in selected brain regions except for the frontal region, the tumour-containing region and the region surrounding the tumour-containing region. Administration of niravoline inhibited the increase in the water content in the brain regions remote from the tumour.
Takahashi
H
H
Department of Neurosurgery, Nippon Medical School Dai-ni Hospital, Kanagawa, Japan.
Hamada
H
H
Teramoto
A
A
D000818:Animals; D044482:Benzeneacetamides; D001834:Body Water / Q000378:metabolism; D001921:Brain / Q000378:metabolism / Q000473:pathology; D001929:Brain Edema / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology* / Q000378:metabolism; D001932:Brain Neoplasms / Q000150:complications*; D005260:Female; D005910:Glioma / Q000150:complications*; D008279:Magnetic Resonance Imaging; D009368:Neoplasm Transplantation; D011759:Pyrrolidines / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D017473:Receptors, Opioid, kappa / Q000819:agonists*
D044482:Benzeneacetamides; D011759:Pyrrolidines; D017473:Receptors, Opioid, kappa; C100946:niravoline